GIOTRIF TABLET

País: Canadá

Idioma: inglés

Fuente: Health Canada

Ingredientes activos:

AFATINIB (AFATINIB DIMALEATE)

Disponible desde:

BOEHRINGER INGELHEIM (CANADA) LTD LTEE

Código ATC:

L01EB03

Designación común internacional (DCI):

AFATINIB

Dosis:

20MG

formulario farmacéutico:

TABLET

Composición:

AFATINIB (AFATINIB DIMALEATE) 20MG

Vía de administración:

ORAL

Unidades en paquete:

28

tipo de receta:

Prescription

Área terapéutica:

ANTINEOPLASTIC AGENTS

Resumen del producto:

Active ingredient group (AIG) number: 0154930001; AHFS:

Estado de Autorización:

APPROVED

Fecha de autorización:

2013-11-01

Ficha técnica

_Pr_
_GIOTRIF® Product Monograph _
_ Page 1 of 44 _
PRODUCT MONOGRAPH
PR
GIOTRIF
®
Afatinib Tablets
20, 30 and 40 mg afatinib (as afatinib dimaleate)
Protein Kinase Inhibitor
Boehringer Ingelheim (Canada) Ltd.
5180 South Service Road
Burlington, Ontario
L7L 5H4
www.boehringer-ingelheim.ca
Date of Revision:
June 6, 2019
Submission Control No: 225731
Giotrif
®
is a registered trademark and used under license from Boehringer
Ingelheim
International GmbH
BICL 0281-09
_Pr_
_GIOTRIF® Product Monograph _
_ Page 2 of 44 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
..................................................................................................11
DRUG INTERACTIONS
..................................................................................................19
DOSAGE AND ADMINISTRATION
..............................................................................20
OVERDOSAGE
................................................................................................................21
ACTION AND CLINICAL PHARMACOLOGY
............................................................22
STORAGE AND STABILITY
..........................................................................................23
SPECIAL HANDLING INSTRUCTIONS
.......................................................................23
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................24
PART II : SCIENTIFIC INFORMATION
............................................................